title: Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
authors.affiliation: Willamette Valley Cancer Institute, Eugene, OR. Electronic address: Jeff.Sharman@USOncology.com.
authors.forename: J P
authors.initials: JP
authors.lastname: Sharman
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: J
authors.initials: J
authors.lastname: Chmielecki
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: D
authors.initials: D
authors.lastname: Morosini
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: G A
authors.initials: GA
authors.lastname: Palmer
authors.affiliation: Foundation Medicine Inc, Cambridge, MA; Albany Medical College, Albany, NY.
authors.forename: J S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Willamette Valley Cancer Institute, Eugene, OR.
authors.forename: J
authors.initials: J
authors.lastname: Stafl
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Foundation Medicine Inc, Cambridge, MA.
authors.forename: S M
authors.initials: SM
authors.lastname: Ali
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002294:Carcinoma, Squamous Cell; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D017809:Fatal Outcome; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D000077269:Lenalidomide; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000235:genetics*; D016609:Neoplasms, Second Primary; D010014:Osteolysis / Q000209:etiology / Q000473:pathology / Q000532:radiotherapy; D010166:Palliative Care; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D016879:Salvage Therapy; D013449:Sulfonamides / Q000627:therapeutic use*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007211:Indoles; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011719:Pyrazines; D013449:Sulfonamides; D000077484:Vemurafenib; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D000077269:Lenalidomide
keywords: Mitogen-activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib